BLTI: Biolase Diode Laser Featured in Live Surgery Broadcast. Strong Buy, IMO. Diode laser already received FDA clearance and is gaining acceptance in the dental surgery community. In the climate that we now have for biotechs. and medical device leaders, IMO, the stock will double by the end of March 2000:
"SAN CLEMENTE, Calif., Feb 29, 2000 /PRNewswire via COMTEX/ --
Biolase Technology, Inc. (Nasdaq: BLTI ), today announced that its
TwiLite(TM) diode laser was demonstrated during a live closed-circuit TV
broadcast from Northwestern University Dental School to an auditorium of
dentists at the Chicago Dental Society's 135th Midwinter Meeting last week. The
demonstration, an aesthetic tissue recontouring surgery, was performed by Peter
Rinaldi, D.M.D., a renowned cosmetic dentist.
Dr. Rinaldi's presentation, "Veneers: A Demonstration in Preparation, Design and
Cementation," focused on the necessary fundamentals for properly preparing and
seating cosmetic veneers. Following the surgery, Dr. Rinaldi commented, "The
TwiLite worked very well and the results were fantastic. I was able to recontour
the tissue without any bleeding. The advantages of using diode lasers are that the
margins are very predictable, there is almost no post-operative discomfort and the
tissue heals very well compared to other technologies. The diode laser is a must
for any dentist performing cosmetic procedures."
Dr. Rinaldi is a renowned cosmetic dentist in private practice with Dr. Larry
Rosenthal in New York City. He is the clinical director for some of the leading
aesthetic hands-on post graduate courses, Aesthetic Advantage, which are
presented at Baylor College of Dentistry, New York University, Palm Beach
Community College and the University of Kentucky College of Dentistry. Dr.
Rinaldi has also published numerous articles on cosmetic dentistry and lectures
extensively.
The TwiLite diode laser, which received clearance from the Food and Drug
Administration in late September 1999, is a revolutionary lightweight laser ideally
suited for a range of soft tissue procedures. It is equipped with robust,
state-of-the-art features favored by dentists, including a "power on demand" foot
switch that allows users to quickly increase or decrease power levels while
continuing treatment.
Dental diode laser sales in the U.S. are projected to increase 300 percent in 2000
over 1999, and an additional 55 percent in 2001, according to a recent
independent study. The study, "U.S. Market for Dental Products 2000,"
prepared by the Millennium Research Group in Toronto, Canada, also projects
that dental diode laser sales will continue to increase more than 20 percent per
year through 2004.
Jeffrey W. Jones, Biolase president and CEO, commented, "Cosmetic
procedures represent a rapidly growing business for dentists, and one of the most
requested procedures is veneers for the anterior teeth. According to the leading
cosmetic dentists, a diode laser is clearly the most effective, and a necessary, tool
for tissue recontouring and 'smile design.'"
Jones added, "In just a short time, Biolase has become the diode laser of choice
among prominent and influential dentists, and that was the reason our laser was
selected for this important demonstration. Attendance at courses for cosmetic
dentistry such as these is growing, fueled by dentists' desire to provide their
patients with additional services, increase revenue and improve the profitability of
their practices. Biolase has already been selected by several of the top courses
and is pursuing opportunities with all of the other most prominent courses and
their key dentists. Having our laser featured at these courses and used by their
dentists are two of the most effective ways to market and sell our feature-rich
TwiLite."
Biolase Technology, Inc. (www.biolase.com), manufactures and markets
advanced dental, cosmetic, aesthetic and surgical products, including
Hydrokinetic(TM) surgical cutting systems and other advanced laser and
non-laser based products for the professional and home consumer market. The
company's products incorporate patented and patent-pending technologies in the
pursuit of painless surgery.
The matters discussed in this news release include forward-looking statements
which are subject to various risks, uncertainties and other factors that could cause
actual results to differ materially from the results anticipated in such
forward-looking statements. Such risks, uncertainties and other factors include,
but are not limited to, the effect of actions of third parties, including governmental
officials, the timely development and acceptance of new products, the impact of
competitive products and pricing, and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission, including the
reports on Forms 10-K and 10-Q. These forward-looking statements represent
the Company's judgment as of the date of this release. The Company disclaims,
however, any intent or obligation to update these forward-looking statements.
SOURCE Biolase Technology, Inc." |
